Cerebrospinal Fluid BACE1 Activity and sAβPPβ as Biomarker Candidates of Alzheimer’s Disease
Authors:
- Polychronis EconomouPEPolychronis Economou
- The Alzheimer’s Disease Neuroimaging InitiativeTIThe Alzheimer’s Disease Neuroimaging Initiative
Open Access
- 22 May 2018
- journal article
- research article
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 45 (3-4) , 152-161
Abstract
Background/Aims: The utility of β-site amyloid-β precursor protein (AβPP) cleaving enzyme 1 (BACE1) activity and soluble AβPP β (sAβPPβ) levels in cerebrospinal fluid (CSF) in detecting Alzheimer’s disease (AD) is still elusive. Methods: BACE1 activity and sAβPPβ concentration were measured in patients with AD dementia (n = 56) and mild cognitive impairment (MCI) due to AD (n = 76) with abnormal routine AD CSF markers, in patients with MCI with normal CSF markers (n = 39), and in controls without preclinical AD (n = 48). In a subsample with available 18F-fluorodeoxyglucose positron emission tomography (FDG PET) data, ordinal regression models were employed to compare the contribution of BACE1 and sAβPPβ to correct diagnostic classification to that of FDG PET. Results: BACE1 activity was significantly higher in patients with MCI due to AD compared to both controls and patients with MCI with normal CSF markers. sAβPPβ did not differ between any of the studied groups. Interestingly, BACE1 activity was not found to be inferior to FDG PET as predictive covariate in differentiating between the diagnostic groups. Conclusions: Further studies using biomarker-underpinned diagnoses are warranted to shed more light on the potential diagnostic utility of BACE1 activity as AD biomarker candidate in MCI.Keywords
This publication has 48 references indexed in Scilit:
- Decreased Clearance of CNS β-Amyloid in Alzheimer’s DiseaseScience, 2010
- Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluidFluids and Barriers of the CNS, 2010
- Comparing predictors of conversion and decline in mild cognitive impairmentNeurology, 2010
- Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolismBMC Neurology, 2010
- Alzheimer's Disease Neuroimaging Initiative (ADNI)Neurology, 2010
- Relationships between biomarkers in aging and dementiaNeurology, 2009
- Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal FluidBiological Psychiatry, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patientsExperimental Neurology, 2003
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002